Previous Close | 106.27 |
Open | 106.00 |
Bid | 0.00 x 1200 |
Ask | 0.00 x 1100 |
Day's Range | 105.60 - 109.44 |
52 Week Range | 62.55 - 113.41 |
Volume | 6,594,042 |
Avg. Volume | 7,363,890 |
Market Cap | 191.934B |
Beta (5Y Monthly) | 0.81 |
PE Ratio (TTM) | 39.96 |
EPS (TTM) | 2.72 |
Earnings Date | Apr 29, 2021 - May 03, 2021 |
Forward Dividend & Yield | 5.20 (4.89%) |
Ex-Dividend Date | Apr 14, 2021 |
1y Target Est | 120.67 |
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In clinical trials, HUMIRA induced clinical remission at Week 8 and maintained remission at Week 52 in patients who responded at Week 8.1,2
* SKYRIZI® is an interleukin-23 (IL-23) inhibitor used for the treatment of moderate to severe plaque psoriasis.1 * In clinical studies, SKYRIZI® significantly improved levels of skin clearance after just 16 weeks and maintained clearance at one year (52 weeks).
In this article we are going to list the top 15 pharmaceutical companies with the highest R&D spending. Click to skip ahead and jump to the Top 5 Pharmaceutical Companies With Highest R&D Spending. Pharma companies have always been among the most important companies in the world, even if they have been much maligned as […]